Search Contract Opportunities

Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus   3

ID: W81K0225QA107 • Type: Synopsis Solicitation • Match:  95%
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Please sign-in to link federal registration and award history to assistant. Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Draft a response outline indicating that my company is also capable of performing this sole source work
Do the documents mention an incumbent contractor?
Does this contract have any security clearance requirements?
I'd like to anonymously submit a question to the procurement officer(s)
Loading

Description

THIS NOTICE OF INTENT IS NOT A REQUEST FOR QUOTES. A DETERMINATION NOT TO COMPETE THE PROPOSED PROCUREMENT BASED UPON RESPONSES TOTHIS NOTICE IS SOLELY WITHIN THE DISCRETION OF THE GOVERNMENT.

Medical Readiness Contracting Office - Pacific hereby provides notice of its intent to award a sole-source, firm fixed price contract under the authority of FAR 13.106-1(b)(1). As a result, the Government intends to award directly to Qiagen, LLC, Germantown, MD, CAGE 01QT0, in accordance with FAR 13.106-1(b)(1). This requirement is expected to be an indefinite delivery indefinite quantity (IDIQ) contract for a 5-year ordering period.

This requirement is for the procurement of QuantiFERON TB Gold-Plus assay reagents for running QuantiFERON TB-Gold Plus for the detection of Mycobacterium Tuberculosis immune responses by enzyme immunoassay (EIA) at Madigan Army Medical Center (MAMC). The government currently utilizes the DiaSorin LIAISON XL analyzer at MAMC to detect latent Mycobacterium tuberculosis infection. QuantiFERON TB Gold-Plus assays are the only FDA-cleared interferon-gamma release assays that can be used on the analyzer at MAMC without the need to purchase and install additional instrumentation for operability that would only result in partial automation. It would also be necessary to obtain additional physical workspace to accommodate the added system, which MAMC does not have. Therefore, only the QuantiFERON-TB Gold Plus reagents can meet the government's requirement to ensure continuity of operations, maintain required testing capacity, and meet DHA reference laboratory obligations.

The attached salient characteristics detail the requirements of this anticipated contract action. Market Research has demonstrated that the intended awardee is the only business that is able to meet the requirements.

THIS NOTICE OF INTENT IS NOT A REQUEST FOR QUOTES; no solicitation or RFQ will be forthcoming.

Any firm that believes it can provide the stated supplies can provide supporting documents demonstrating their capabilities and certifications. Interested parties may identify their interest and capability to respond to this requirement no later than Wednesday, 17 September 2025 at 11:00 AM Pacific Time.

All documents submitted will not be returned. Responses received may be used for future acquisitions. All interested parties shall submit clear and convincing documentation demonstrating their capabilities to satisfy the requirements contained within the attached Statement of Work. The capability documentation should include general information and technical background describing in detail the prospective contractor's capabilities and experience that will demonstrate the ability to support these requirements.

Interested parties are encouraged to furnish information by email only with subject line stating - RESPONSE TO INTENT TO SOLE SOURCE FOR W81K0225QA107. Information can be sent to Brittany Chartier at brittany.n.chartier.civ@health.mil. No telephone or facsimile requests will be accepted. This procurement will be prepared in accordance with FAR Part 13, Simplified Acquisition Procedures.

Medical Readiness Contracting Office - Pacific will NOT be responsible for any costs incurred by interested parties in responding to this notice of intent. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

Background
The Medical Readiness Contracting Office - Pacific intends to award a sole-source, firm fixed price contract to Qiagen, LLC, located in Germantown, MD. This contract is expected to be an indefinite delivery indefinite quantity (IDIQ) contract for a 5-year ordering period. The goal of this contract is to procure QuantiFERON TB Gold-Plus assay reagents necessary for the detection of Mycobacterium Tuberculosis immune responses at Madigan Army Medical Center (MAMC).

The government currently uses the DiaSorin LIAISON XL analyzer at MAMC for testing latent Mycobacterium tuberculosis infection, and only the QuantiFERON TB Gold-Plus assays are FDA-cleared for use on this analyzer without requiring additional instrumentation or workspace.

Work Details
The contract will involve the procurement of QuantiFERON TB Gold-Plus assay reagents and controls with the following salient characteristics:
1) Bar-coded data entry capabilities;
2) FDA-cleared Interferon-gamma release assay for detecting Mycobacterium tuberculosis infection;
3) Fully automated assay to minimize manual intervention during analysis;
4) Alignment with existing Defense Health Agency (DHA) laboratory operations and reference testing mandates;
5) Assay must be performed on DiaSorin LIAISON XL;
6) Ready-to-use reagents and bar-coded cassettes;
7) Automatic calculations for results interpretation with direct reporting of qualitative (positive/negative) and quantitative (IU/ml) results to the Laboratory Information System (LIS).

Place of Performance
The products will be delivered and utilized at Madigan Army Medical Center (MAMC).

Overview

Response Deadline
Sept. 17, 2025, 2:00 p.m. EDT Past Due
Posted
Sept. 16, 2025, 1:01 p.m. EDT
Set Aside
None
Place of Performance
Tacoma, WA United States
Source

Current SBA Size Standard
1250 Employees
Pricing
Fixed Price
Est. Level of Competition
Sole Source
Est. Value Range
Experimental
<$250,000 (solicitation indicates Simplified Acquisition Procedures, which in most cases, applies to contracts expected to be less than $250K in value)
Vehicle Type
Indefinite Delivery Contract
On 9/16/25 Medical Command issued Synopsis Solicitation W81K0225QA107 for Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus due 9/17/25. The opportunity was issued full & open with NAICS 325413 and PSC 6550.
Primary Contact
Name
Brittany Chartier   Profile
Phone
None

Documents

Posted documents for Synopsis Solicitation W81K0225QA107

Question & Answer

The AI Q&A Assistant has moved to the bottom right of the page

Opportunity Lifecycle

Procurement notices related to Synopsis Solicitation W81K0225QA107

Award Notifications

Agency published notification of awards for Synopsis Solicitation W81K0225QA107

IDV Awards

Indefinite delivery vehicles awarded through Synopsis Solicitation W81K0225QA107

Incumbent or Similar Awards

Contracts Similar to Synopsis Solicitation W81K0225QA107

Potential Bidders and Partners

Awardees that have won contracts similar to Synopsis Solicitation W81K0225QA107

Similar Active Opportunities

Open contract opportunities similar to Synopsis Solicitation W81K0225QA107

Experts for Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus

Recommended subject matter experts available for hire

Additional Details

Source Agency Hierarchy
DEPT OF DEFENSE > DEPT OF THE ARMY > MEDCOM > W40M REGIONAL HEALTH CONTRACTING OF
FPDS Organization Code
2100-W81K02
Source Organization Code
100221346
Last Updated
Oct. 3, 2025
Last Updated By
brittany.n.chartier.civ@health.mil
Archive Date
Oct. 2, 2025